m+Medelevator.RU
← Поиск публикаций
Journal of Ayurveda and integrative medicine · 2026

A preliminary study on Tapyadi Loha for the treatment of hepatic encephalopathy based on Insilico and Invitro analysis.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Chindam Shruti, Aswar Urmila, Phondekar Chinmay

Аннотация

BACKGROUND: Hepatic encephalopathy (HE) is a neuropsychiatric disorder linked to liver dysfunction, commonly occurring in cirrhosis or acute liver failure. Existing treatments like lactulose and rifaximin provide only symptomatic relief and cause gastrointestinal side effects, emphasizing the need for alternative therapies. Tapyadi Loha (TL), a classical Ayurvedic herbomineral formulation, is traditionally used in clinical practice for HE lacks scientific evidence.

OBJECTIVES: To perform preliminary evaluation of TL in the management of HE through in silico and in vitro analysis.

MATERIAL AND METHODS: Activity markers of TL were screened using IMPPAT, SwissADME, and MolSoft based on ≥30 % oral bioavailability and drug-likeness scores of 0-1. Potential HE-related targets were identified through SwissTarget Prediction, SuperPred, BindingDB, and GeneCards, with overlapping targets analyzed via PPI networks using STRING and Cytoscape. Molecular docking in Schrodinger's Maestro revealed good binding affinity phytoconstituents, which were quantified by LC-MS/MS as per CCRAS guidelines. Their hepatoprotective activity was validated in HepG2 cells, while antioxidant effects were confirmed using the DPPH assay.

RESULTS: Gene ontology and KEGG analyses revealed enrichment in cancer and hepatitis B pathways, notably NF-κB, TNF, and TLR signalling. Docking studies identified strong binding of gallic acid, quercetin, ascorbic acid, and luteolin, validated by LC-MS/MS. In vitro, TL treatment significantly improved HepG2 cell viability in thioacetamide-induced toxicity in a dose dependent manner, confirming its hepatoprotective potential. Additionally, TL demonstrated antioxidant activity in the DPPH assay.

CONCLUSION: The study examined the potential molecular targets, important genes, and signalling pathways of TL and its connection to HE using a network pharmacology approach. HepG2 cell line research showed that TL increased cell viability in a dose-dependent way. The study supports TL's possible neuroprotective and hepatoprotective benefits.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты